Daniel Yerace's most recent trade in Coeptis Therapeutics Holdings Inc was a trade of 20,000 Common Stock done . Disclosure was reported to the exchange on Feb. 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Coeptis Therapeutics Holdings Inc | Daniel Yerace | Director, VP Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 20,000 | 70,531 | - | 0 | Common Stock | |
| Coeptis Therapeutics Holdings Inc | Daniel Yerace | Director, VP Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.41 per share. | 11 Feb 2026 | 10,000 | 70,531 | - | 10.4 | 104,100 | Common stock |
| Coeptis Therapeutics Holdings Inc | Daniel Yerace | Director, VP of Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 5,000 | 25,000 | - | - | Non-Qualified Stock Options (right to buy) | |
| Coeptis Therapeutics Holdings Inc | Daniel Yerace | Director, VP of Operations | Purchase of securities on an exchange or from another person at price $ 0.69 per share. | 05 Jan 2024 | 10,850 | 1,071,455 | - | 0.7 | 7,487 | Common Stock |
| Coeptis Therapeutics Holdings Inc | Daniel Yerace | Director, VP of Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 200,000 | 200,000 | - | - | Incentive Stock Options (right to buy) |